Orlistat
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
Empros Pharma AB · Phase 1/2 · Completed · Enrollment 156
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| EMP16-02 120 mg orlistat/40 mg acarbose | n/r | n/r | n/r | n/r | n/r |
| EMP16-02 150 mg orlistat/50 mg acarbose | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.